TRPC4 and focal segmental glomerulosclerosis: Inhibitors of TRPC4/5 are mostly used to target renal diseases such as focal segmental glomerulosclerosis (FSGS) (Mundel et al., 2019; Zhou et al., 2017), but can also have a therapeutic effect on the central nervous system (CNS) (Just et al., 2018; Yang et al., 2015).